Ascendis Pharma A/S (ASND) Q1 2020 Earnings Results

Ascendis Pharma A/S Misses on EPS, Stock Up 1.72%

Ascendis Pharma reported a loss of $1.44 per share, which was slightly below expectations. Despite the loss, the stock rose by 1.72%, indicating that investors may have reacted positively to other aspects of the company's performance or future potential. However, without guidance or management commentary, it's difficult to assess the company's outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.44	N/A	-0.76%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

Ascendis Pharma A/S Misses on EPS, Stock Up 1.72%

Key numbers

Management commentary

Ascendis Pharma A/S

More earnings this week

Ascendis Pharma A/S Misses on EPS, Stock Up 1.72%

Key numbers

Management commentary